Rhinovirus Diagnostics Global Market Report 2026

Rhinovirus diagnostics refer to laboratory and clinical testing methods used to detect and confirm rhinovirus infections, which are the most common cause of the common cold. These diagnostic procedures typically involve analyzing respiratory samples using advanced molecular techniques for rapid and accurate virus identification. Rhinovirus diagnostics support healthcare professionals in making timely treatment decisions, controlling the spread of infection, and improving overall patient care and disease management.

The primary offerings in rhinovirus diagnostics include kits and assays, instruments and platforms, and services and software. Kits and assays refer to ready-to-use diagnostic test solutions designed for detecting rhinovirus infections in clinical samples. These diagnostics utilize technologies such as molecular diagnostics, antigen detection, and serological testing. They are applied to sample types including nasal swabs, throat swabs, nasopharyngeal aspirates, and others, and are used by end users such as hospitals, diagnostic laboratories, clinics, and others.

Tariffs are influencing the rhinovirus diagnostics market by increasing the cost of importing critical diagnostic components such as PCR reagents, assay kits, molecular probes, and advanced diagnostic instruments used in viral detection. This is disrupting global supply chains, particularly affecting diagnostic laboratories and hospitals in import-dependent regions such as Asia-Pacific and Latin America. Segments like molecular diagnostic kits and next-generation sequencing platforms are most affected due to their reliance on high-precision imported technologies and reagents. However, tariffs are also encouraging local manufacturing of diagnostic kits, strengthening regional supply chains, and driving investment in domestic diagnostic infrastructure and innovation, supporting long-term market resilience.

The rhinovirus diagnostics market size has grown strongly in recent years. It will grow from $1.58 billion in 2025 to $1.71 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing prevalence of common cold and respiratory infections globally, rising adoption of molecular diagnostic techniques for viral detection, growth in hospital laboratory testing infrastructure, limitations of traditional culture-based virus detection methods, and increasing awareness of early infectious disease diagnosis.

The rhinovirus diagnostics market size is expected to see strong growth in the next few years. It will grow to $2.33 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to rising demand for rapid point-of-care diagnostic solutions, integration of AI-based diagnostic interpretation tools, expansion of multiplex respiratory pathogen testing panels, increasing investment in infectious disease surveillance systems, and growth in personalized and precision medicine approaches for respiratory infections. Major trends in the forecast period include AI-assisted rapid respiratory pathogen detection and interpretation, expansion of multiplex PCR-based respiratory virus panels, growth of point-of-care rhinovirus diagnostic testing devices, integration of cloud-based infectious disease surveillance platforms, and advancements in high-sensitivity molecular diagnostic assays for early detection.

The rising prevalence of respiratory disorders is expected to propel the growth of the rhinovirus diagnostics market in the coming years. Respiratory disorders are conditions that affect the lungs and airways, making it difficult for individuals to breathe and properly exchange oxygen. The incidence of respiratory disorders is increasing mainly due to rising air pollution, which damages the lungs through continuous exposure to harmful pollutants and gradually weakens respiratory health over time. Rhinovirus diagnostics help in respiratory disorders by rapidly detecting rhinovirus infections, enabling timely and accurate treatment decisions that prevent complications and reduce the spread of respiratory illnesses. For instance, in December 2023, according to the National Center for Biotechnology Information, a US-based government agency, cases of Chronic Obstructive Pulmonary Disease (COPD) are expected to rise by 112 million, reaching a total of 592 million by 2050, accounting for 9.5% of the total eligible population. Therefore, the rising prevalence of respiratory disorders is driving the growth of the rhinovirus diagnostics market.

Major companies operating in the rhinovirus diagnostics market are focusing on developing innovative solutions such as rapid syndromic molecular diagnostics platforms to enable fast, accurate, and multiplex detection of respiratory pathogens for improved clinical decision-making. A rapid syndromic molecular diagnostics platform is a testing system that simultaneously identifies multiple pathogens from a single sample using molecular methods, enabling fast and accurate diagnosis of infections. For instance, in April 2023, bioMerieux S.A., a France-based biotechnology company, received U.S. Food and Drug Administration (FDA) 510(k) clearance for the BIOFIRE SPOTFIRE Respiratory (R) Panel Mini and announced plans to pursue CLIA-waiver status for the system. The panel is designed to rapidly detect multiple respiratory pathogens, including human rhinovirus/enterovirus, directly at the point of care. It supports faster diagnosis, streamlined workflow efficiency, and timely treatment decisions in outpatient and emergency care settings.

The rising healthcare expenditure is expected to propel the growth of the rhinovirus diagnostics market going forward. Healthcare expenditure refers to the total financial resources spent by individuals, organizations, or governments on preventing, treating, and managing health conditions. Healthcare expenditure is increasing due to advancements in medical technology, as new diagnostic tools, treatments, and innovative therapies often come with higher costs, leading to greater overall spending on healthcare. Higher healthcare expenditure supports rhinovirus diagnostics by enabling improved access to advanced testing technologies, strengthening diagnostic infrastructure, and increasing patient affordability and testing rates. For instance, in April 2025, according to the Office for National Statistics, a UK-based independent producer of official statistics, in 2024, the UK's healthcare spending reached approximately $29.88 billion (£317 billion), reflecting a 6.5% nominal increase compared with 2023. Therefore, the rising healthcare expenditure is driving the growth of the rhinovirus diagnostics market.

Major companies operating in the rhinovirus diagnostics market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Quest Diagnostics Incorporated, Danaher Corporation (Cepheid), Hologic Inc., Bruker Corporation (ELITechGroup SAS), bioMerieux SA, Qiagen N.V., QuidelOrtho Corporation, DiaSorin S.p.A., Seegene Inc., ARUP Laboratories Inc., Sansure Biotech Inc., SRL Inc., R-Biopharm AG, CerTest Biotec S.L., SpeeDx Pty Ltd, GeneFirst Limited, Atila BioSystems Inc.

North America was the dominant region in the rhinovirus diagnostics market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in rhinovirus diagnostics report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the rhinovirus diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rhinovirus diagnostics market consists of revenues earned by entities by providing services such as respiratory pathogen panel testing, rapid antigen testing, and sample collection services. The market value includes the value of related goods sold by the service provider or included within the service offering. The Rhinovirus diagnostics market also includes sales of PCR analyzers, real-time PCR machines, NGS sequencing instruments, and point-of-care testing devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The rhinovirus diagnostics market research report is one of a series of new reports from The Business Research Company that provides rhinovirus diagnostics market statistics, including rhinovirus diagnostics industry global market size, regional shares, competitors with a rhinovirus diagnostics market share, detailed rhinovirus diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the rhinovirus diagnostics industry. This rhinovirus diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rhinovirus Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses rhinovirus diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rhinovirus diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rhinovirus diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Offering: Kits And Assays; Instruments And Platforms; Services And Software
• 2) By Technology: Molecular Diagnostics; Antigen Detection; Serology
• 3) By Sample Type: Nasal Swabs; Throat Swabs; Nasopharyngeal Aspirates; Other Sample Types
• 4) By End User: Hospitals; Diagnostic Laboratories; Clinics; Other End Users
• Subsegments:
• 1) By Kits And Assays: Molecular Diagnostic Kits (Polymerase Chain Reaction Based Assays); Rapid Antigen Detection Kits; Multiplex Respiratory Pathogen Panels
• 2) By Instruments And Platforms: Automated Immunoassay Analyzers; Point Of Care Diagnostic Devices; Next Generation Sequencing Platforms
• 3) By Services And Software: Laboratory Information Management Systems; Diagnostic Data Interpretation Software; Cloud Based Reporting And Surveillance Platforms
• Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc.; Abbott Laboratories; Becton Dickinson and Company; Quest Diagnostics Incorporated; Danaher Corporation (Cepheid); Hologic Inc.; Bruker Corporation (ELITechGroup SAS); bioMerieux SA; Qiagen N.V.; QuidelOrtho Corporation; DiaSorin S.p.A.; Seegene Inc.; ARUP Laboratories Inc.; Sansure Biotech Inc.; SRL Inc.; R-Biopharm AG; CerTest Biotec S.L.; SpeeDx Pty Ltd; GeneFirst Limited; Atila BioSystems Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.